Lena Torlegård

Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam. IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.

Shortcut Media Group är en snabbväxande mediakoncern som består av följande varumärken: - Bond Street Film: Produktion av reklamfilm, high-end företagsfilm samt trailers, promos och relaterade digitala tjänster - Oddway Film: Prisbelönt, Göteborgsbaserat filmproduktionsbolag som kombinerar kreativitet och strategi inom reklam-, brand- och imagefilm med fokus på storytelling. Har även ett representationskontor i Dubai. - Magoo: Söderhamns-baserad kreativ studio inriktad på avancerad 3d-animation, VFX och inspelad film med inslag av VFX samt animation. Kunder finns primärt i Sverige samt i USA, där bolaget har representationskontor i New York. - Shortcut Produktion: Produktion av företags-, beställnings- och animerad film. Efterbearbetning av TV-serier, reklam-, företags- och myndighetsfilm. - Frost Studio: Stockholmsbaserad produktionsstudio specialiserad på 3d-animation samt visuella effekter och animation till bl.a. företagsfilm, digitala/sociala medier, långfilm samt reklamfilmsproduktioner. - Good Motion: Specialiserade på high-end 3D-animation, VR samt visuella effekter till reklam- och företagsfilm, TV och drama. Koncernen finns i Stockholm, Göteborg, Söderhamn med representationskontor i New York samt Dubai och sysselsätter drygt 70 st heltidstjänster.

Flowscape is a proptech company that embrace the idea of modern offices. We swear our allegiance to the notion of free movement, flowing communication and total accessibility that derives from working close together. But at the same time, we condemn the friction caused by not optimizing workplaces. We believe that spending time searching for meeting rooms, desks, equipment and colleagues creates irritating friction. This friction is translated into decreased productivity, hampered work relations and lower overall well-being. And as an end result, a vast number of hidden costs. Our field of knowledge is our state of the art technology, designed for offices. But frankly, we know that it is not about impressive specs or advanced algorithms. It is about understanding that everybody wants to do a good job and not waste time. Flowscape exists to minimize time wasting and tear down barriers for interaction. To make employees around the world love working in modern offices. This is why we get up in the morning. Do you want join the quest?

Nanologica is a Swedish biotechnology company developing nanoporous silica particles for applications within life science. The company is world-leading in controlling the shape, size, and type of porosity of silica particles, creating opportunities to develop unique products. Through the two business areas, Chromatography and Drug Development, the company strives towards increasing the accessibility for innovative treatments and medicines in healthcare, for the benefit of patients around the world. In Chromatography, the company aims to make insulin and other peptide-based drugs available to more patients in need by providing a purification product that lowers manufacturing cost by being more efficient and lasting longer than competitors. In Drug Development, Nanologica develops a unique drug delivery platform for local delivery of drugs to the lung. The platform for inhalation is developed to provide new treatment options for patients with severe lung diseases. Nanologica’s stock (NICA) is listed on Nasdaq Main Market. For further information, please visit www.nanologica.com.

Synartro is a Swedish pharmaceutical company developing local injection treatments aiming to provide superior and sustained efficacy without systemic side-effects. This is achieved by combining our patented delivery technology with existing proven drugs. Our pre-clinical lead program focuses on a novel therapy using our compound SYN321 for the treatment of osteoarthritis (OA). Currently this disease leaves up to 50% of patients without adequate pain relief.

Annexin Pharmaceuticals AB (publ) is a world-leading biotechnology company in the Annexin A5 field, for the treatment of various cardiovascular diseases. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with cardiovascular diseases with vascular damages and inflammation. The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of Annexin A5. The production process is patented. ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack. ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.

IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's . In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam. IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB’s strong clinical pipeline, the company is also progressing two preclinical programs, IRL942 and IRL757, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.

"Välkommen till en av Sveriges snabbast växande arkitekturbyråer. Vi rekryterar kunder och medarbetare som delar vår tanke att passionerade människor kan förändra världen."​ Vi på Codesign är en samling människor med olika kompetenser och personligheter. Inte en enda av oss som jobbar här har fått jobbet för sin spjutspetskompetens utan för att vi är spjutspetspersonligheter som är kompetenta. Organisationer består av människor med olika sorters behov. Dessa behov tar vi fasta på i våra uppdrag. Vi är övertygade om att samverkan ger det bästa resultatet. Därför sker våra projekt tillsammans med snickare, producenter, fastighetsägare förvaltare och inte minst med er, våra kunder. Vi verkar tillsammans och då blir det bra. Tillsammans tar vi reda på hur vi kan göra människor lyckligare, smartare och bättre. Där, i den meningen får vi vår lust och energi, svårare är det inte. /Codesign

Shortcut Media Group är en snabbväxande mediakoncern som består av följande varumärken: - Bond Street Film: Produktion av reklamfilm, high-end företagsfilm samt trailers, promos och relaterade digitala tjänster - Oddway Film: Prisbelönt, Göteborgsbaserat filmproduktionsbolag som kombinerar kreativitet och strategi inom reklam-, brand- och imagefilm med fokus på storytelling. Har även ett representationskontor i Dubai. - Magoo: Söderhamns-baserad kreativ studio inriktad på avancerad 3d-animation, VFX och inspelad film med inslag av VFX samt animation. Kunder finns primärt i Sverige samt i USA, där bolaget har representationskontor i New York. - Shortcut Produktion: Produktion av företags-, beställnings- och animerad film. Efterbearbetning av TV-serier, reklam-, företags- och myndighetsfilm. - Frost Studio: Stockholmsbaserad produktionsstudio specialiserad på 3d-animation samt visuella effekter och animation till bl.a. företagsfilm, digitala/sociala medier, långfilm samt reklamfilmsproduktioner. - Good Motion: Specialiserade på high-end 3D-animation, VR samt visuella effekter till reklam- och företagsfilm, TV och drama. Koncernen finns i Stockholm, Göteborg, Söderhamn med representationskontor i New York samt Dubai och sysselsätter drygt 70 st heltidstjänster.